Latest news and press releases about Arcutis Biotherapeutics, Inc. (ARQT): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds.
Price
| Price | $26.14 |
| Market Cap | $3.3B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 116.28 |
| Price / Book | 15.19 |
| EV / EBITDA | 1475.09 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -8.52% |
| Return on Invested Capital | -4.02% |
| Return on Assets | -3.73% |
| Gross Margin | 91.14% |
| Operating Margin | 7.38% |
| Net Margin | 6.15% |
Related companies: CELC · CGON · CNTA · FOLD · IRON · LEGN · TARS
Explore sector: Healthcare · Biotechnology
More sections of ARQT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks